San Diego, CA, United States of America

Roger Paul Bakale

This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignee: Kura Oncology, Inc.. Active years: 2025-2026.

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 6.4

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Roger Paul Bakale

Introduction

Roger Paul Bakale is a notable inventor based in San Diego, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds and formulations. With a total of 3 patents, Bakale's work is focused on advancing cancer treatment methodologies.

Latest Patents

Bakale's latest patents include "Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same." This patent relates to solid forms of a compound that can be used in pharmaceutical compositions for treating cancer dependent on a farnesylated protein. Another significant patent is for "Crystalline forms of a menin inhibitor," which describes crystalline forms of a specific compound that may have therapeutic applications.

Career Highlights

Roger Paul Bakale is currently associated with Kura Oncology, Inc., where he continues to innovate in the pharmaceutical sector. His work is pivotal in developing new treatments that could potentially improve patient outcomes in oncology.

Collaborations

Throughout his career, Bakale has collaborated with notable colleagues, including Patricia Andres and Craig Michael Bowe. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Roger Paul Bakale's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to improving cancer treatment options. His work at Kura Oncology, Inc. and collaborations with esteemed colleagues further underscore his impact in the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…